CXCR4 and cancer: Based on our review of 85 studies in over 11,000 patients with cancer, we show that over-expression of CXCR4 is associated with worse prognosis in terms of OS and PFS in different types of tumors, which suggests that the development of strategies against this receptor could be a reasonable therapeutic approach.